Genmab and Janssen Biotech, both big biotech companies has agreed to collaborate in biotech partnering agreement to create and develop antibodies using its DuoBody technology platform and will receive an upfront payment of $3.5 million.
Under the terms of this biotech partnering deal, Janssen will fully fund the research to be done at Genmab, and Genmab will potentially be entitled to milestone and license payments of up to about $175 million for each product as well as royalties on any commercialized products.
The biotech partnering deal with Janssen followed a collaboration agreement with Novartis in June to use Genmab’s DuoBody technology.
The DuoBody platform, introduced in 2010 is a technology for the discovery and development of antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity